Invest In
Revolutionizing the Way to Treat Neurodegenerative Disease.
Almost all of us know–or will know–someone who suffers from Alzheimer’s, Parkinson’s, Multiple Sclerosis, PTSD, or another debilitating brain disease. It’s difficult to see people we love struggle so much–and it’s even more difficult to find treatment options that are simple, non-invasive, and effective. . . until now.
The Problem
The Cost of Doing Nothing
The cumulative physical, emotional, and financial effect of Central Nervous System (CNS) disorders on patients and their caretakers is utterly devastating. The latest data projects that by 2025, the number of people suffering from Alzheimer’s alone is set to increase by 22%–putting enormous strain on our healthcare system, not to mention the families who care for their aging loved ones.
What does an investment in Kurve Therapeutics mean?
the cognitive aging market
The solution
The ViaNase™ Difference
Researchers and scientists have spent the last 25 years trying and failing to develop effective treatments for brain diseases. The majority of the traditional treatments methods available can’t bypass the blood brain barrier, leaving the majority of the medication behind in the nasal cavity, sinuses, or GI tract. Other methods also can produce a number of undesirable side effects.
ViaNase™ Intelligent Delivery holds the key to overcoming this frustrating obstacle. This modified approach to treating Central Nervous System disorders uses Kurve Therapeutics’ patented Controlled Particle Dispersion technology to deliver medication precisely where it is needed, providing relief and a sense of wellbeing for patients battling brain disease.
01
Reduction in systemic side effects
02
Enhances the opportunity for bioavailability
03
Non-invasive / painless
04
Odorless / tasteless
05
User-friendly
06
Increased patient compliance
07
Convenient / portable
08
Lightweight / pocket-sized
09
Battery powered
10
Fast and easy to administer
The Proof
Thoroughly Vetted
Kurve Therapeutics’ revolutionary treatment system is featured in 18 peer-reviewed publications by
leading institutions such as:
clinical trials
Rigorously Tested
We hold to the highest levels of transparency and integrity when it comes to sharing the results of our ongoing clinical trial phase. So far, we’ve met our endpoints in 3 separate clinical trials (Phase 2b) and are cleared to begin Phase 3. Here’s the latest trials we’ve participated in where our next-generation technology was the device of choice:
*Clinical trial reports available upon request
The Opportunity
Here’s where you come in.
In 2022, Kurve Therapeutics filed a Regulation A offering with the SEC. This means we can officially offer investment opportunities for the general public to partner with us as we continue to conduct clinical studies. If these studies prove successful–and all indications are favorable that they will–we will officially move into the next stages of product development and launch.
1 billion people around the world suffer from neurological disorders. And every 3 seconds, someone in the world develops dementia.
If dementia were a country, it would have a $1.3 trillion market size and the 14th largest economy in the world.
Our mission is to break new ground in the treatment of brain disorders and bring hope to those suffering with limited or ineffective treatment options.
The offering
Shape The Future With Us
It’s simple. With your partnership, we have the unprecedented opportunity to change the lives of millions of people battling CNS disorders and give their families the best gift of all: peace of mind. There’s never been a better time to get in on the ground floor of this unprecedented opportunity.
$50M
Total Filing Raise
$580
Minimum Investment
$5.80
Price Per Share
Video Introduction
Kurve is at the forefront of a new era of central nervous system disorder treatments.
About Kurve Therapeutics
Our Mission and Vision
To put it simply: we do this because we can and because we have to.
Our mission is to help as many people as we possibly can in their fight with neurodegenerative disorders. Our hope is that these complex debilitating disorders may have a solution when paired with the right medication and the right technology. Our goal is to enhance the quality of life for patients and provide a solution where their past treatments have failed them–to give people a renewed sense of hope for the future.
The Team Behind Kurve
Meet Our Medtech Innovators
Marc Giroux
CHAIRMAN & CHIEF EXECUTIVE OFFICER
Marc’s lifelong battle with chronic sinusitis and allergies pushed him to develop a new intranasal therapy solution that would actually work. His background in high-end manufacturing and product development gave him the tools he needed to invent a better option for intranasally delivered treatments. After developing Kurve’s patented delivery system, he realized that he could utilize this technology in ways beyond sinus and allergy treatments.
Glenn Cornett, M.D., Ph.D.
CHIEF SCIENCE OFFICER
Dr. Glenn Cornett is a biotech entrepreneur and advisor. He holds an M.D. with Distinction in Research from the University of Michigan and a Ph.D. in neuroscience from UCLA. He has spent the past decade developing drugs for psychiatric and neurological indications.
Tom S. McDowell
CHIEF OPERATING OFFICER
Tom is a skilled and accomplished COO with forty years of experience in accounting, financial reporting, investment banking, and mergers & acquisitions for established and start-up companies. He has consulted with over 25 startups and early-stage companies in the software, telecommunications, financial management, retail, manufacturing, consulting and distribution industries.